Skip to main content
Premium Trial:

Request an Annual Quote

Guardant360 CDx Receives CE Mark for Tumor Mutational Profiling and Tagrisso CDx Use

NEW YORK – Guardant Health said today that its Guardant360 CDx liquid biopsy test has received the CE mark for tumor mutation profiling in cancer patients with any solid tumor. The assay is also approved as a companion diagnostic to identify non-small cell lung cancer patients who may benefit from treatment with osimertinib (AstraZeneca's Tagrisso).

Guardant360 CDx is a targeted sequencing assay performed on blood samples, which detects alterations in a panel of 55 genes with established actionability in guiding the use of molecularly targeted cancer drugs.

The test received US Food and Drug Administration approval for these same indications in August 2020, and Guardant CEO Helmy Eltoukhy said in a statement that extending this to a CE mark is an important step in now making the assay internationally accessible.

"We are committed to helping cancer patients be comprehensively tested to see if they are appropriate for potentially life-changing personalized treatments," Eltoukhy said.

While the assay is only approved for the one companion diagnostic indication so far, Guardant is collaborating with several pharmaceutical companies including Amgen, Janssen Biotech, and Radius Health to establish Guardant360 as a response predictor for other drugs.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.